Print

Purpose

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy: - Diffuse large B-cell lymphoma - not otherwise specified - High-grade B-cell lymphoma - Diffuse large B-cell lymphoma - transformed from indolent lymphomas - Follicular large B-cell lymphoma - Follicular lymphoma - Other non-Hodgkin lymphoma - Has measurable disease - Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy

Exclusion Criteria

  • Has an active second cancer - Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval. - Has known Cytomegalovirus infection. Participants with negative status are eligible - Has known hepatitis B or C infection or uncontrolled HIV - Has known significant heart disease

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Phase 1a-Monotherapy Dose Escalation (Cohort A1) 		LY4584180 monotherapy administered orally
  • Drug: LY4584180
    administered orally
Experimental
Phase 1a-Monotherapy Dose Optimization (Cohort A2) 		LY4584180 monotherapy administered orally
  • Drug: LY4584180
    administered orally
Experimental
Phase 1b-Dose Expansion-Monotherapy (Cohort B1-B3) 		LY4584180 monotherapy administered orally
  • Drug: LY4584180
    administered orally
Experimental
Phase 1b-Dose Expansion-Combination (Cohort B4) 		LY4584180 administered orally in combination with rituximab administered through IV infusion
  • Drug: LY4584180
    administered orally
  • Drug: Rituximab
    administered through IV infusion

Recruiting Locations

City of Hope
Duarte, California 91010

Colorado Blood Cancer Institute
Denver, Colorado 80218

Florida Cancer Specialists - Sarasota
Sarasota, Florida 34236

Emory University Hospital
Atlanta, Georgia 30322

Massachusetts General Hospital
Boston, Massachusetts 02114

Dana-Farber Cancer Institute
Boston, Massachusetts 02215

Columbia University
New York, New York 10032

University of Rochester
Rochester, New York 14618

The Ohio State University (OSU)
Columbus, Ohio 43210

Sarah Cannon Research Institute
Nashville, Tennessee 37203

Vanderbilt University Medical Center
Nashville, Tennessee 37212

Texas Oncology - DFW (Sammons CC)
Dallas, Texas 75246

University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)
Seattle, Washington 98195

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.